News
NICE rejects rare blood cancer treatment Poteligeo in final appraisal
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Kyowa Kirin’s Poteligeo for the treatment of adults living with rare blood cancers in its final appraisal document (FAD).